Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($) $ in Thousands			3 Months Ended						9 Months Ended
	Mar. 09, 2023	Mar. 10, 2022	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Jul. 31, 2023	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from Sale of Equity Method Investments		$ 130,000
Reduction in workforce											86.00%
Net income			$ (32,954)	$ (35,044)	$ (28,844)	$ (33,726)	$ (29,089)	$ 92,105	$ (96,842)	$ 29,290
Loss from operations			(31,001)			$ (32,862)			(89,328)	$ (98,787)
Accumulated deficit			$ 525,979						$ 525,979			$ 429,137
Oxford Biomedica Plc
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Upfront Payment Received		130,000
Proceeds from Sale of Equity Method Investments		$ 50,000
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net proceed from issuance of common stock	$ 250,000
ATM
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Share									0
Proceeds through future financings									$ 75,000
ATM | Oxford Biomedica Plc
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction		80.00%
ATM | Homology Member
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction		20.00%
ATM | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings	$ 75,000